NCT03995472 2023-09-28
A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
Clinical Trials
15 trialsNCT04025957 2023-09-28
A Study of SHR-1501 in Patients With Advanced Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT04353830 2023-03-01
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT04831944 2022-08-26
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.
Incyte Corporation
Phase 1 Completed
NCT04831996 2022-08-17
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.
Incyte Corporation
Phase 1 Completed
NCT03717103 2022-04-07
A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03763149 2021-12-06
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03158272 2020-12-21
A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread
Bristol-Myers Squibb
Phase 1 Completed
NCT00426140 2020-12-08
Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.
Novartis
Phase 1 Completed
NCT00651664 2019-03-15
A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies
Takeda
Phase 1 Completed
NCT00500903 2019-03-14
A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT02678260 2018-06-08
Phase I Study of PDR001 in Patients With Advanced Malignancies.
Novartis
Phase 1 Completed
NCT02013804 2017-10-06
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
MedImmune LLC
Phase 1 Completed
NCT00955084 2010-09-24
Maintenance Study on the Long Term Safety of XL999
Symphony Evolution, Inc.
Phase 1 Completed
NCT00083525 2008-01-24
Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies
Heidelberg Pharma AG
Phase 1 Completed